Paradigm Submits Phase 3 OA Program to FDA
Company Announcements

Paradigm Submits Phase 3 OA Program to FDA

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Paradigm Biopharmaceuticals Ltd. has made significant strides by submitting a comprehensive package, including new nonclinical study results and phase 2 clinical trial data, to the US FDA in hopes of advancing its phase 3 osteoarthritis program. The submission includes a draft protocol for the upcoming pivotal trial and a revised safety plan, with the company aiming to commence patient enrollment in the second half of 2024, pending FDA feedback. Additionally, Paradigm is preparing for TGA provisional approval in Australia, which could accelerate access to their innovative osteoarthritis treatment and potentially lead to earlier revenue generation.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharma Advances Phase 3 Trials Amid Financial Prudence
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharmaceuticals Advances Phase 3 Trial Plans
TipRanks Australian Auto-Generated NewsdeskParadigm Biopharmaceuticals Plans New Securities Issuance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App